Laborecom Therapeutics
PrivateLast Round
Grant
Jan 1, 2026
Company Overview
Laborecom Therapeutics is a biotechnology company developing LBRC-101, a first-in-class peptide therapeutic that prevents cancer metastasis, and other therapies for reperfusion injury.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Laborecom Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Laborecom Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 1, 2026 | ||||
| Grant | Sep 15, 2025 |
Laborecom Therapeutics Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
$75K grant received from Illinois Department of Commerce.
- Sep 15, 2025
$388K grant received from the National Heart, Lung, and Blood Institute.
Laborecom Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Laborecom Therapeutics's valuation, stock price, and market status.
